Veracyte Inc (VCYT):企業のM&A・提携動向(医療機器分野)

GlobalDataが発行した調査報告書(GDME73376D)
◆英語タイトル:Veracyte Inc (VCYT) - Medical Equipment - Deals and Alliances Profile
◆商品コード:GDME73376D
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年1月25日
◆ページ数:44
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Veracyte Inc (Veracyte) is a diagnostics company that develops solutions in the field of molecular cytology. The company’s pipeline products include Afirma thyroid FNA analysis for the diagnosis of thyroid cancer based on its proprietary Afirma Gene Expression Classifier. Its products also include Percepta bronchial genomic classifier, an assay to evaluate patients with lung nodules that are suspected for cancer. Veracyte provides genomic testing to other areas of substantial clinical need with diagnostic ambiguity. It markets Afirma solutions in the US through its sales force. The company also commercializes its products in Brazil. Veracyte is headquartered in South San Francisco, California, the US.

Veracyte Inc (VCYT) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Veracyte Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Veracyte Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Veracyte Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Veracyte Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Veracyte Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Veracyte Inc, Medical Equipment, Deal Details 11
Venture Financing 11
Veracyte Raises US$28 Million In Series C Financing 11
Veracyte Secures USD14.95 Million in Venture Funding 12
Allegro Diagnostics Plans To Raise Up To US$20 Million In Series B Financing 13
Allegro Diagnostics Secures Additional US$5.4 Million In Series A Financing 13
Partnerships 14
Allegro Diagnostics Enters Into Licensing Agreement With Boston University And The University of Utah 14
Veracyte Enters into Research Agreement with GE Healthcare 15
Veracyte Enters into Co-Promotion Agreement with Genzyme 16
Genzyme Extends Co-Promotion Agreement with Veracyte 17
Genzyme Enters Into Co-Marketing Agreement With Veracyte 18
Equity Offering 19
Veracyte Prices Public Offering of Shares for USD30 Million 19
Veracyte to Raise USD40 Million in Private Placement of Shares 20
Veracyte Completes IPO For US$65 Million 21
Acquisition 22
Veracyte Acquires Allegro Diagnostics for USD21 Million 22
Veracyte Inc – Key Competitors 24
Key Employees 25
Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Strategy And Business Planning 27
Jan 07, 2016: Veracyte Announces Expansion to New South San Francisco Facility 27
Financial Announcements 28
Nov 03, 2016: Veracyte Announces Third Quarter 2016 Financial Results 28
Oct 17, 2016: Veracyte Releases Preliminary Third Quarter 2016 Financial Results 29
Aug 03, 2016: Veracyte Announces Second Quarter 2016 Financial Results 30
May 05, 2016: Veracyte Announces First Quarter 2016 Financial Results 31
Mar 10, 2016: Veracyte Announces Fourth Quarter and Full-Year 2015 Financial Results, Provides 2016 Financial Outlook 32
Corporate Communications 33
Dec 13, 2016: Veracyte Announces Appointment of Kevin K. Gordon and Other Changes to Its Board of Directors 33
Nov 21, 2016: Veracyte appoints new CFO 34
Jun 13, 2016: Veracyte Announces Resignation of Its Chief Financial Officer 35
Product News 36
Mar 22, 2016: New Study Supports Use of Veracyte’s Medullary Thyroid Cancer Classifier as Part of Its Comprehensive Afirma Solution 36
Mar 16, 2016: New Data Show That Veracyte’s Afirma Gene Expression Classifier Reduces Unnecessary Thyroid Surgeries and Costs During Long-Term Follow-Up 37
Feb 29, 2016: Veracyte Announces Publication of Data Confirming Analytical Verification of Percepta Bronchial Genomic Classifier 38
Feb 25, 2016: Veracyte Announces Publication of Data Supporting Clinical Utility of the Percepta Bronchial Genomic Classifier in Lung Cancer Diagnosis 39
Feb 19, 2016: Veracyte Announces Publication of Study Reinforcing the Clinical Utility of the Afirma Gene Expression Classifier in Thyroid Cancer Diagnosis 40
Jan 28, 2016: Veracyte Receives Regulatory Authorization to Offer Percepta Bronchial Genomic Classifier for Patients in New York State 41
Jan 22, 2016: Veracyte Announces Publication of Long-Term Clinical Utility Study for the Afirma Gene Expression Classifier 42
Clinical Trials 43
Mar 22, 2016: New Study Supports Use of Veracyte’s Medullary Thyroid Cancer Classifier as Part of Its Comprehensive Afirma Solution 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Veracyte Inc, Medical Equipment, Key Facts, 2015 1
Veracyte Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
Veracyte Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Veracyte Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Veracyte Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Veracyte Inc, Deals By Market, 2011 to YTD 2017 9
Veracyte Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Veracyte Raises US$28 Million In Series C Financing 11
Veracyte Secures USD14.95 Million in Venture Funding 12
Allegro Diagnostics Plans To Raise Up To US$20 Million In Series B Financing 13
Allegro Diagnostics Secures Additional US$5.4 Million In Series A Financing 13
Allegro Diagnostics Enters Into Licensing Agreement With Boston University And The University of Utah 14
Veracyte Enters into Research Agreement with GE Healthcare 15
Veracyte Enters into Co-Promotion Agreement with Genzyme 16
Genzyme Extends Co-Promotion Agreement with Veracyte 17
Genzyme Enters Into Co-Marketing Agreement With Veracyte 18
Veracyte Prices Public Offering of Shares for USD30 Million 19
Veracyte to Raise USD40 Million in Private Placement of Shares 20
Veracyte Completes IPO For US$65 Million 21
Veracyte Acquires Allegro Diagnostics for USD21 Million 22
Veracyte Inc, Key Competitors 24
Veracyte Inc, Key Employees 25
Veracyte Inc, Other Locations 26
Veracyte Inc, Subsidiaries 26

List of Figures
Veracyte Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
Veracyte Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
Veracyte Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
Veracyte Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
Veracyte Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Veracyte Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 7
Veracyte Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Veracyte Inc, Medical Equipment, Deals by Market, 2011 to YTD 2017 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Veracyte Inc (VCYT):企業のM&A・提携動向(医療機器分野)(Veracyte Inc (VCYT) - Medical Equipment - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆